The Genetics of Cancer: Is Personalization of Cancer Treatment Possible?

KEITH T. FLAHERTY, MD
Dr. Flaherty is director of the Henri and Belinda Termeer Center for Targeted Therapies at the Mass General Cancer Center and Associate Professor of Medicine at Harvard Medical School. Dr. Flaherty’s research and clinical focus is therapies for melanoma, with a particular expertise in targeted therapies.

Dr. Flaherty has been awarded numerous grants from the National Cancer Institute, including K23, RO1, and PO1 grants. He has been the principal investigator of many clinical trials, including first-in-human trials of novel targeted therapies, and two NCI cooperative group trials. He is a member of numerous scientific cancer societies and national committees, and has authored many research articles, abstracts and reviews in the peer-reviewed literature; including 3 first-author New England Journal of Medicine papers. He serves as a senior editor for Clinical Cancer Research and a member of the editorial boards for Cancer Discovery, Journal of Clinical Oncology, Cancer, and Pigment Cell and Melanoma Biology.

Dr. Flaherty obtained his undergraduate degree from Yale University in 1993 and an MD from Johns Hopkins University in 1997. He completed his internship in medicine, followed by a residency in medicine, at Brigham and Women’s Hospital (Harvard Medical School) in Boston. He went on to complete a fellowship in Medical Oncology at the Hospital of the University of Pennsylvania.

Dr. Flaherty came to Mass General from the University of Pennsylvania Abramson Cancer Center where he was an Assistant Professor of Medicine at the University of Pennsylvania School of Medicine and an Adjunct Professor at the Wistar Institute.

Do New Cancer Care Payment Systems Foster or Thwart the Delivery of the Right Treatment at the Right Time?

ROBERT W. CARLSON, MD
Dr. Carlson is the Chief Executive Officer (CEO) at the National Comprehensive Cancer Network (NCCN). He joined NCCN as CEO in January 2013 following an esteemed history of leadership positions within the organization including, most notably, Representative to the NCCN Board of Directors, Chair of the Breast Cancer Guidelines Panel, Member and Founding Chair of the Breast Cancer Risk Reduction Guidelines Panel, and Chair of the Survivorship Guidelines Panel.

Prior to his appointment as CEO at NCCN, Dr. Carlson served as Professor of Medicine in the Division of Oncology and Stanford Medical Informatics at Stanford University Medical Center, as well as Medical Director of inpatient oncology and hematology at Stanford Cancer Institute in Stanford, California. Dr. Carlson is a graduate of Stanford University Medical School, and he completed his internship and junior residency in internal medicine at Barnes Hospital Group in St. Louis, Missouri before returning to
Stanford University to complete his senior residency. He earned a Bachelor of Science with distinction from Stanford University, specializing in biological sciences. Dr. Carlson is board certified in Medical Oncology and Internal Medicine.

Dr. Carlson is a member of several medical societies, including American College of Physicians (ACP), American Association for Cancer Research (AACR), and the American Society of Clinical Oncology (ASCO). Dr. Carlson lectures extensively and has authored or co-authored more than 140 articles, abstracts, and book chapters, which have appeared in publications such as Journal of the National Cancer Institute, Journal of Clinical Oncology, and The Breast Journal. He has served as Associate Editor of Oncology and JNCCN — Journal of the National Comprehensive Cancer Network.

From 2001 to 2012, Dr. Carlson was selected by America’s Top Doctors; from 1994 to 2011, he was selected by Best Doctors in America; in 2008, he was presented with the National Physician of the Year Award for Clinical Excellence by Castle Connolly Medical, Ltd.; and in 2010, Dr. Carlson was given the Founding Collaborator Award by the Breast Health Global Initiative (BHGI).

THOMAS W. FEELEY, MD

Thomas W. Feeley is the Helen Shafer Fly Distinguished Professor of Anesthesiology and Professor of Health Services Research at the University of Texas MD Anderson Cancer Center. He also heads the Institute for Cancer Care Innovation at MD Anderson. He has a joint faculty appointment at the Harvard Business School where he is a Senior Fellow in the Institute for Strategy and Competitiveness. Dr. Feeley received both undergraduate and M.D. degrees from Boston University and trained in anesthesiology and critical care at Boston’s Beth Israel Hospital. He was a faculty member at Stanford University for 19 years practicing cardiovascular anesthesia and critical care. In 1997 he came to MD Anderson to create and lead the Division of Anesthesiology and Critical Care. The Division of Anesthesiology and Critical Care became the largest program of its kind devoted to cancer anesthesiology and critical care.

His work with the Institute for Cancer Care Innovation focuses on research to demonstrate and improve the value of cancer care delivery. Dr. Feeley recently served on the Institute of Medicine’s Committee on Improving the Quality of Cancer Care: Addressing the Needs of an Aging Population that produced the report titled Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis that was released in September of 2013. Dr. Feeley was appointed by former Texas Governor Rick Perry to the Board of Directors of the Institute for Health Care Quality and Efficiency. At the Harvard Business School Dr. Feeley works in the Institute for Strategy and Competitiveness with Professor Michael Porter and Robert Kaplan on research and education projects related to value-based health care. In addition to his research and education roles, Dr Feeley provides patient care services in the delivery of anesthesia.

MICHAEL FISCH, MD, MPH

Michael J. Fisch, MD, MPH, is Professor and Chair of the Department of General Oncology and Medical Director of the Community Clinical Oncology Program in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston, TX. He earned his MD from the University of Virginia School of Medicine and his master’s degree in Public Health from Indiana University in Bloomington, IN. He completed a residency in Internal Medicine at University of Virginia and fellowships
in Hematology/Oncology and general internal medicine (Health Services Research) at Indiana University. He is board certified in Medical Oncology, and Hospice and Palliative Medicine. Dr. Fisch is a fellow of both the American College of Physicians and the American Academy of Hospice and Palliative Medicine.

Dr. Fisch’s research interests include palliative care, symptom management, cardio-oncology, social media in medicine, and health care disparities. He has been published in the Journal of Clinical Oncology, the Journal of the National Cancer Institute, and numerous other peer-reviewed journals. He has also authored or co-authored several book chapters and books. He has been an invited speaker at various national and international conferences. He is an active volunteer for the American Society of Clinical Oncology (ASCO), where he has held leadership positions. He is currently serving as Chair of the ASCO Palliative Care in Oncology Symposium. He is also an active blogger for ASCO and for MD Anderson, as well as being active on twitter @fischmd. Dr. Fisch is currently the Chair of the Symptom Management Committee of ECOG-ACRIN and Co-Chair of the Symptom Management and Quality of Life Steering Committee for the National Cancer Institute (NCI). In addition, he serves on the NCI National Clinical Trials Network (NCTN) Working Group.

RON KLINE, MD
Ron Kline is a board certified pediatric hematologist-oncologist. In his role as a medical officer in the Patient Care Models Group at the Center for Medicare and Medicaid Innovation (CMMI), he is part of the program team directing CMS’s new Oncology Care Model. As a Robert Wood Johnson Foundation Health Policy Fellow in 2013-14, he focused on health policy in the office of Senate Finance Committee Chair Ron Wyden and at CMMI.

He has been a clinical pediatric hematologist–oncologist for over 20 years, most recently serving as the medical director of the Pediatric Division of Comprehensive Cancer Centers of Nevada, the largest multispecialty oncology group in Nevada. He is a clinical associate professor at the University of Nevada School of Medicine.

Kline has held leadership positions in local and statewide organizations, primarily focusing on health policy and children’s issues. He is past president of the Clark County Medical Society and the Nevada State Medical Association, a former alternate delegate to the American Medical Association House of Delegates, a past gubernatorial appointee to the Silver State Health Insurance Exchange board of directors, and a former member of the Nevada Board of Medical Examiners. He was the founding chair of the Children’s Medical Advocacy Coalition and president elect of the Southern Nevada Medical Industry Coalition. In addition to his medical and health policy pursuits, Kline has a strong interest in history and international relations, having served as an officer of the World Affairs Council of Las Vegas from 2008-2013.

Kline has broad experience directing clinical programs in multiple states and in university, hospital-based, and private practice settings. He is the author of over 20 scientific publications, and the editor of a textbook on pediatric hematopoietic stem cell transplantation.
Kline received his MD and BA from the University of California, Los Angeles, and did his pediatric residency training at the Children’s Hospital of Los Angeles. He completed a biotechnology fellowship at the National Cancer Institute and a clinical fellowship in pediatric hematology-oncology and hematopoietic stem cell transplantation at the University of California, San Francisco.

**LEE NEWCOMER, MD, MHA**

Dr. Newcomer is a senior vice president at UnitedHealthcare with strategic responsibility for Oncology, Genetics and Women’s Health.

Dr. Newcomer is a board certified medical oncologist; he practiced medical oncology for nine years in Tulsa, Oklahoma, and Minneapolis (Park Nicollet Clinic). He is the former chairman of Park Nicollet Health Services (now HealthPartners), an integrated system of physicians and hospitals in the Minneapolis and St. Paul metropolitan area. The group is nationally recognized for its leadership in quality, safety and cost-effectiveness.

Dr. Newcomer began his management career as a medical director for CIGNA Health Care of Kansas City in 1990. From 1991 to 2000, Dr. Newcomer was the chief medical officer at UnitedHealthcare where his work emphasized the development of performance measures and incentives to improve clinical care. Dr. Newcomer was a founding executive of Vivius, a consumer directed venture that allowed consumers to create their own personalized health plans. He returned to UnitedHealthcare in 2006 to focus on combining clinical, financial and administrative incentives for improved and affordable cancer care.

Dr. Newcomer earned a B.A. degree from Nebraska Wesleyan University, an M.D. degree from the University of Nebraska College of Medicine, and a Masters of Health Administration from the University of Wisconsin at Madison. He completed his internship and residency in internal medicine at the University of Nebraska Medical Center and a fellowship in medical oncology at the Yale University School of Medicine.

**FREDERICK P. SMITH, MD**

Dr Fred Smith is a practicing Medical Oncologist in the DC Metropolitan Area and holds a Clinical appointment as Associate Professor of Medicine at Georgetown University having pursued five years of academic research during that tenure at the Lombardi Cancer Research Center. He has contributed several publications during that time and continues to pursue a keen interest in Clinical research in Breast, Lung, Colorectal, Ovarian and Lymphoma in his community practice.

As a consequence, he remains very much in touch with the realities of patient care while maintaining a cutting-edge cancer care focused on the comfort and satisfaction of each patient and family. He represents an excellent bridge for both the academic and private practice communities.

**GAIL R. WILENSKY, PhD**

Dr. Wilensky is an economist and senior fellow at Project HOPE, an international health foundation. She directed the Medicare and Medicaid programs and served in the White House as a senior adviser on health and welfare issues to President GHW Bush. She was also the first chair of the Medicare Payment
Advisory Commission. Her expertise is on strategies to reform health care, with particular emphasis on Medicare, comparative effectiveness research and military health care.

Dr. Wilensky currently serves as a trustee of the Combined Benefits Fund of the United Mine Workers of America and the National Opinion Research Center, is on the Board of Regents of the Uniformed Services University of the Health Sciences (USUHS), the Visiting Committee of the Harvard Medical School and the Board of Directors of the Geisinger Health System Foundation. She is an elected member of the Institute of Medicine, served two terms on its governing council and currently chairs the Healthcare Servicing Board. She is a former chair of the board of directors of Academy Health, a former trustee of the American Heart Association and a current or former director of numerous other non-profit organizations. Dr. Wilensky testifies frequently before Congressional committees, serves as an adviser to members of Congress and other elected officials, and speaks nationally and internationally. She received a bachelor’s degree in psychology and a Ph.D. in economics at the University of Michigan and has received several honorary degrees.

**FDA and the Challenges of Cancer Drug Review in the 21st Century: Immunotherapies, Targeted Therapies, and Companion Diagnostics**

**MARTHA DONOHUE, MD**

Martha Donoghue is a Medical Officer with the Neuro-Oncology, Pediatric Oncology, and Rare Tumors Team in the Division of Oncology Products 2, Office of Hematology and Oncology Products (OHOP), Center for Drug Evaluation and Research (CDER), United States Food and Drug Administration (FDA). She is also OHOP’s Scientific Liaison for Pediatric Solid Tumors. Dr. Donoghue provides regulatory oversight, engages in clinical review activities, and advises stakeholders involved in the development of drugs and therapeutic biologics for the diagnosis, prevention, and treatment of cancer. Dr. Donoghue has also served as a member of several FDA and external working groups aimed at advancing development of treatments for pediatric and adult patients with cancer. Areas of special interest include neuroblastoma, neuro-oncology, and the use of innovative designs and clinical outcome assessments in clinical trials. Prior to joining FDA in 2009, Dr. Donoghue completed a fellowship in pediatric hematology and oncology at the Children’s National Medical Center after having worked for several years as a general pediatrician in private practice.

**How Can Cancer Patients and Oncology Professionals Collaborate in Decision-Making that Will Improve Care Planning and Coordination?**

**CLAIRE SNYDER, MHS, PHD**

Claire Snyder, PhD, is Associate Professor of Medicine, Division of General Internal Medicine, at the Johns Hopkins School of Medicine with joint appointments in Oncology and Health Policy & Management (Bloomberg School of Public Health). She directs the Program for Building Lifestyle, Outcomes, and Care Services Research in Cancer (BLOCS) at Johns Hopkins. Her research focuses on the quality of cancer care, with emphasis in two areas: quality of life for cancer patients undergoing treatment and coordination of care for cancer survivors. She has conducted studies to investigate preventive and comorbid condition care in cancer survivors and has also applied her research to
developing survivorship care strategies at Johns Hopkins. In other research, she is investigating whether having cancer patients complete questionnaires about their quality-of-life and supportive care needs, and providing that information to their clinicians, improves care quality. Dr. Snyder is President-Elect of the International Society for Quality of Life Research and a former member of the Health Services Committee and Quality of Care Committee of the American Society of Clinical Oncology (ASCO). Previously, Dr. Snyder worked at the National Cancer Institute and edited Outcomes Assessment in Cancer: Measures, Methods, and Applications (Cambridge University Press). She began her career in the private sector at Covance Health Economics and Outcomes Services Inc. Dr. Snyder received a BA cum laude in Public Policy Studies with a certificate in Health Policy from Duke University. She received a Master of Health Science in Health Policy in 2000 and a PhD in Health Policy & Management in 2005 from the Johns Hopkins Bloomberg School of Public Health. Dr. Snyder is originally from New Orleans, Louisiana, and currently resides in Baltimore, Maryland.

**VICKI JACKSON, MD, MPH**

Dr. Jackson is the Chief of the Palliative Care Division at Massachusetts General Hospital and Associate Professor, Department of Medicine, Harvard Medical School. She was the former Fellowship Director for the Harvard Palliative Medicine Fellowship. She completed residency and chief residency in Internal Medicine at The Cambridge Hospital, Harvard Medical School. She pursued training in research methods through the Harvard General Medicine Fellowship and completed a Master’s in Public Health at The Harvard School of Public Health. She completed training in palliative care at The Dana-Farber Cancer Institute and Brigham and Women’s Hospital. She joined the faculty of Massachusetts General Hospital in 2002. She pursued further research training in the Program for Cancer Outcomes Training. She was selected in 2003 for the Harvard Academy Education Fellowship where her work focused on the development of end of life medical and communication curriculum which was the basis for the curriculum for the Harvard Palliative Medicine Fellowship. In 2009, she was selected as the Rabkin Fellow in Medical Education at The Beth Israel Hospital.

Currently, she is the Palliative Care lead investigator for a grant funded by the National Institutes of Health investigating the effect of early ambulatory palliative care for patients with advanced cancer. Her work focuses on developing curricula to train others in the communication skills required to deliver this care. She spends much of her time developing, teaching, and evaluating palliative medicine curricula for medical students, residents, fellows, and faculty. Nationally she served as Co-Chair for an innovative 3 year academic leadership training program for junior palliative medicine faculty with American Academy of Hospice and Palliative Medicine. She also served as the Co-Editor for a series devoted to the clinician-educator in The Journal of Palliative Medicine. Her work has been featured in the New York Times, Boston Globe, and on ABC World News Tonight.

**MARLENE KING**

Marlene King was diagnosed with Ductal Carcinoma in Situ (DCIS) in 2008 at the age of 48; at which time, she elected to have a lumpectomy, chemotherapy and radiation. After treatments the cancer seemed to be in remission. In 2011, the cancer returned and she decided it would be best to have to a double mastectomy and reconstructive surgery.
However, one year later in 2012, Marlene was diagnosed with stage 4 metastatic breast cancer; the prognosis for life expectancy 4-36 months. During this time, Marlene decided to connect with META vivor and overtime made it her priority to be an activist through the organization in raising awareness about the facts about metastatic (stage 4) breast cancer.

Even though Marlene struggles with this disease, she is tenacious in her goal to enjoy life. Marlene is committed to empowering women through advocacy, offering support and sharing information about breast cancer in its entire characteristic. She has actively advocated for women’s wellness by sharing her personal story in various venues; such as, The Baltimore Sun, The Baltimore Times, area hospitals, City Hall and various cancer sponsored events.

Marlene is a board member of META vivor and currently serves as the President and co-founder of The Journey Continues, a breast cancer organization founded in 2014. The Journey Continues is a non-profit breast cancer organization. Its mission is to raise awareness, inform and empower persons in minority communities through C.A.R.E. (Comfort, Advocacy, Resources and Education).

Marlene shares a thirty year marriage with her life partner Eric King, Sr. They are proud parents of three wonderful sons Eric II, Bryant, and Aston; as well as, two beautiful grandchildren Taylor Morgan and Xavier Wellington King.

WALTER F. BAILE, MD

Walter F. Baile, M.D. is Distinguished Teaching Professor at the University of Texas MD Anderson Cancer Center in Houston, Texas where he holds appointments in the Departments of Psychiatry, Behavioral Science and Faculty & Academic Career Enhancement (FACE). In addition to his psychiatric practice at MD Anderson, he is the Director of the MD Anderson program on Interpersonal Communication and Relationship Enhancement (I*CARE). This educational effort within FACE conducts research, develops and promotes competency in clinician-patient and staff communication. Activities directed toward this goal include a video-based website (www.mdanderson.org/icare), a lecture series for fellows on Professionalism and Communication skills and hands-on workshops on communication and interpersonal skills for faculty, fellows and oncology staff.

Dr. Baile has been involved on a national level in NCI funded programs in teaching communication skills (Oncotalk and Oncotalk Teach) and the International level, training oncologists and other medical professionals in communication skills, notably in Southern Europe, Germany and Japan. He has presented and published widely in the area of clinician-patient communication and is currently co-chair of the American Society of Clinical Oncology panel on Communication Guidelines. His work has received a number of awards. These include the 2010 “People’s Telly Award” for I*CARE website content in three categories: education, training and the highest honor which is the silver People’s Telly Award. The website also received the 2012 eHealthcare Leadership Award for Best Healthcare Content in the subcategory of Physician/Clinician Focused Site. Dr. Baile is also a recipient the 2010 Lynn Payer award given for Outstanding Contributions to the Literature on the Theory, Practice and Teaching of Effective Health Care Communication and Related Skills by the American Association of Communication in Healthcare; the 2012 John P. McGovern Award for Excellence in Biomedical Communication presented by American
Medical Writers Association and in 2013 the University of Texas Regent's Award for Outstanding Teaching and in 2015 the David A Kipper Scholar Award from the American Society of Group Psychotherapy and Psychodrama.

**Professional Society Partnerships to Improve Cancer Care: How will the ASCO-CAP Partnership Improve the Targeting of Cancer Care?**

**RICHARD L. SCHILSKY, MD, FACP, FASCO**

Richard L. Schilsky, MD, FASCO, is the Chief Medical Officer (CMO) of ASCO. He assumed this newly created position with the Society in February of 2013. Formerly the Chief of Hematology/Oncology in the Department of Medicine and Deputy Director of the University of Chicago Comprehensive Cancer Center, he is a highly respected leader in the field of clinical oncology, who specializes in new drug development and treatment of gastrointestinal cancers. Dr. Schilsky is a Past President of ASCO, having served in the role during 2008-2009, and also a Past Chair of one of the National Cancer Institute’s Cooperative Groups, Cancer and Leukemia Group B (CALGB).

Dr. Schilsky’s impressive experience and contributions to the field encompass a deep passion for and track record of accomplishments in cancer medicine; experience in both clinical medicine and clinical research; prior leadership within ASCO; and an in-depth understanding of the current trends and issues affecting oncology clinical practice. He has spent the majority of his career at the University of Chicago where he joined the faculty in 1984 subsequently rising to the rank of Professor of Medicine and serving, in many roles including Associate Dean for Clinical Research in the Biological Sciences Division and as the Director of the University of Chicago Cancer Research Center.

From 1995 to 2010, Dr. Schilsky served as chair of the Cancer and Leukemia Group B, a national cooperative clinical research group funded by the National Cancer Institute (NCI). He has extensive experience working with both the NCI and the Food and Drug Administration having served as a member and chair of the NCI Board of Scientific Advisors, as a member of the NCI Clinical and Translational Research Committee, and as a member and chair of the Oncologic Drugs Advisory Committee of the FDA. Dr. Schilsky has served on the editorial boards of many cancer journals including the *Journal of Clinical Oncology* and, most recently was an Associate Editor of the *Journal of the National Cancer Institute* and Senior Associate Editor of *Molecular Oncology*, among others.

Early in his career he worked in the Clinical Pharmacology Branch of the Division of Cancer Treatment at the NCI, and was an Assistant Professor in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Missouri-Columbia School of Medicine, and was the head of the hematology/medical oncology unit at the Harry S. Truman Veterans’ Administration Hospital in Columbia, Missouri.

**JENNIFER L. HUNT, MD, MED**

Dr. Jennifer Hunt is the Chair of Pathology at the University of Arkansas for Medical Sciences, where she holds the endowed Aubrey J. Hough Endowed Professorship. Dr. Hunt was an undergraduate at Bryn Mawr College and then pursued her Masters of Education and medical degree at the University of
Pennsylvania. She has held prior academic appointments at the University of Pittsburgh, the Cleveland Clinic, and Harvard Medical School. She has served on numerous committees with the College of American Pathologists, including the Curriculum Committee, Council on Membership and Professional Development, and the Publications committee, and has been an active member of the United States and Canadian Association for Pathology, including past service on the Education Committee and as an elected member of the Board. She was elected into several leadership positions in the Association for Molecular Pathology, including most recently as the President of the organization in 2013. In 2014, Dr. Hunt was elected as a member of the Board of Governors of the College of American Pathologists and is currently serving in her first term. She has received awards for leadership, scientific contributions, and teaching, including the Lansky Award, the Arthur Purdy Stout Award, and the CAP Award for Excellence in Teaching. Dr. Hunt has authored over 150 publications in Endocrine, Head & Neck, and Molecular Pathology and Quality Assurance. Her research has focused on the study of tumor associated genetic alterations and mutations in neoplasia, with a strong emphasis on translational applications to improve and expand molecular diagnostic testing for understanding tumor pathogenesis, prognosis, and improved diagnostics.

King v. Burwell: What Comes Next?

LEN NICHOLS, PHD
Len Nichols has been the Director of the Center for Health Policy Research and Ethics (CHPRE) and a Professor of Health Policy at George Mason University since 2010, where he continues to bridge the worlds of health policy, health politics, health economics, health services research, and to help interpret it all for policy makers, private sector leaders, and journalists. Len is the PI of a 5 year evaluation study of the CareFirst Patient Centered Medical Home program. He has testified frequently before Congress and state legislatures, and is or has been an advisor to the Center for Medicare and Medicaid Innovation, the Patient Centered Primary Care Collaborative, and to the Pan American Health Organization. Len has worked with the Commonwealth’s official Health Reform Initiative and the new Virginia Center for Health Innovation as well as with Fairfax County on its own health reform implementation options. Past positions include Senior Advisor for Health Policy at the Office of Management and Budget, Vice President of the Center for Studying Health System Change, Principal Research Associate at the Urban Institute, and chair of the Department of Economics at Wellesley College. He received his Ph.D. from the University of Illinois.

CHRIS JENNINGS
Chris Jennings is an over three decades-long health policy veteran of the White House, the Congress and the private sector. In early 2014, he departed from his second tour of duty in the White House where he served President Obama as the Senior Advisor and Coordinator of Health Reform. He served in a similar capacity in the Clinton White House for nearly eight years.

From his positions in the executive branch, Mr. Jennings has helped implement the Affordable Care Act’s access and delivery reform provisions (for President Obama) as well as played leadership roles in the development, passage and implementation of bipartisan health reforms, such as the Children’s Health Insurance Program and major Medicare reforms in the Balanced Budget Act (BBA) of 1997 (for President
Clinton). In his decade of service in the U.S. Senate, he served as the Deputy Director of the Special Committee on Aging for three Senators (Glenn, Pryor, and Melcher) and led major reform efforts in the areas of long-term care, prescription drug coverage/cost containment, and rural health care.

Outside of government service, Mr. Jennings has been a senior health policy advisor to six Presidential campaigns, including to one of his former bosses, Hillary Clinton. Recognizing his pragmatic nature and experience with key policymakers and stakeholders, the Bipartisan Policy Center (BPC) utilizes him as a senior advisor for numerous health reform projects. In 2014, Mr. Jennings re-established Jennings Policy Strategies (JPS), a nationally respected health care consulting firm committed to assisting foundations, purchasers, health systems and other aligned stakeholders develop policies to ensure higher quality, more affordable and sustainable health care.

**JOSEPH ANTOS, PHD**
Joseph Antos is the Wilson H. Taylor Scholar in Health Care and Retirement Policy at the American Enterprise Institute (AEI), where his research focuses on the economics of health policy — including the Affordable Care Act, Medicare, the uninsured, and the overall reform of the health care system and its financing. He also studies the impact of health care expenditures on federal budget policy.

Before joining AEI, Antos was assistant director for health and human resources at the Congressional Budget Office (CBO). He has also held senior positions in the US Department of Health and Human Services, the Office of Management and Budget, and the President’s Council of Economic Advisers. He recently completed a seven-year term as health adviser to CBO, and two terms as a commissioner of the Maryland Health Services Cost Review Commission. In 2013, he was also named adjunct associate professor of emergency medicine at George Washington University.

Antos has a Ph.D. and an M.A. in economics from the University of Rochester and a B.A. in mathematics from Cornell University.

**STUART BUTLER, PHD**
Stuart Butler is a Senior Fellow at the Brookings Institution. Prior to joining Brookings, Butler spent 35 years at The Heritage Foundation, as Director of the Center for Policy Innovation and earlier as Vice-President for Domestic and Economic Policy Studies. He is also currently an Adjunct Professor at Georgetown’s McCourt School of Public Policy and a Visiting Fellow at the Convergence Center for Policy Resolution. He is a member of the editorial board of Health Affairs, serves on the panel of health advisers for the Congressional Budget Office, and is a member of the Board on Health Care Services of the Institute of Medicine. He also serves on advisory councils for the National Coalition for Cancer Survivorship, the Kaiser Institute for Health Policy, and the March of Dimes. In 2002 he was an Institute of Politics Fellow at Harvard University. In 1990, he served as a member of Housing Secretary Jack Kemp’s Advisory Commission on Regulatory Barriers to Affordable Housing.

Most recently, he has played a prominent role in the debate over health care and reform, arguing for solutions based on individual choice and market competition. He has also been working on a wide range of other issues, including the future of higher education, economic mobility, budget process reform and federal entitlement reform.
Stuart Butler was born in Shrewsbury, England and emigrated to the United States in 1975. He was educated at St. Andrews University in Scotland, where he received a Bachelor of Science degree in physics and mathematics in 1968, a Master of Arts degree in economics and history in 1971, and a Ph.D. in American economic history in 1978.

NCCS Staff and Counsel

SHELLEY FULD NASSO, MPP
Shelley Fuld Nasso is Chief Executive Officer of the National Coalition for Cancer Survivorship. She serves as a member of the National Cancer Institute’s National Council of Research Advisors and the American Society of Clinical Oncology’s Cancer Survivorship Committee. Prior to joining NCCS, Shelley served in leadership roles at Susan G. Komen, where she leveraged the strength of Komen’s grassroots network to strengthen the organization’s reputation and visibility in Washington, D.C., and in state capitals. Shelley has also served as Director of Community Philanthropy at The Dallas Foundation and held management positions at communications and technology enterprises. She is a graduate of Rice University and holds a Master of Public Policy from the Harvard Kennedy School. Her commitment to the work of NCCS is strongly tied to the experiences in the cancer care system of her dear friend, Dr. Brent Whitworth, a beloved physician diagnosed with stage IV cancer days before his 42nd birthday. Through Brent’s battle, Shelley witnessed the strengths and flaws of the cancer care system and embraces the notion that policy change can directly benefit patients and caregivers going through this journey.

ELLEN L. STOVALL
Ellen L. Stovall is a 42-year survivor of three bouts with cancer and has been advocating for more than 30 years to improve cancer care in America. Ms. Stovall is the Senior Health Policy Advisor at the National Coalition for Cancer Survivorship and was a founding member of the Institute of Medicine’s National Cancer Policy Board and its successor, the National Cancer Policy Forum. The Forum allows government, industry, academic and survivor advocacy representatives to meet and privately discuss public policy issues that arise in the prevention, control, diagnosis and treatment of cancer. Prior to the establishment of the Forum, Stovall was vice-chair of the National Cancer Policy Board and co-chaired its Committee on Cancer Survivorship. In that capacity, she co-edited the Institute of Medicine’s report "From Cancer Patient to Cancer Survivor: Lost in Transition," which addressed the issues adult cancer survivors face.

Ms. Stovall served as vice-chair of The Robert Wood Johnson Foundation's National Advisory Committee to Promote Excellence in Care at the End of Life, and as the vice-chair of the Foundation's National Advisory Committee for Pursuing Perfection: Raising the Bar for Health Care Performance. Ms. Stovall served on the Boards of Directors of the National Committee for Quality Assurance (NCQA) and The Leapfrog Group, and she served on a committee of the National Quality Forum (NQF) to establish consensus around cancer care quality measures.

In 2010, Ms. Stovall co-chaired with Dr. George Isham, an NQF Committee convened for the purpose of creating a Measure Development and Endorsement Agenda for the Department of Health and Human Services (HHS) as well as serving on an IOM Committee charged with recommending Standards for
Developing Trustworthy Clinical Practice Guidelines. Ms. Stovall has served on several advisory panels, working groups and committees of the National Cancer Institute (NCI), American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO. Ms. Stovall also served a six-year term on the National Cancer Institute’s National Cancer Advisory Board (NCAB), an appointment she received in 1992 from President Bill Clinton.

SAM TURNER, JD
Sam Turner is a partner in the law and public policy firm Turner & Goss LLP. He is former Deputy General Counsel for the U.S. Department of Health and Human Services (HHS), where he was responsible for legal advice to the entire range of HHS programs, including Medicare and Medicaid, the Food and Drug Administration and the National Institutes of Health. Sam currently advises clients regarding development of new therapies for cancer and other life-threatening diseases. He has been involved in legislation related to coverage of oral anti-cancer drugs, off-label uses of cancer therapeutics, and cancer clinical trials. He has served on the Boards of CancerCare and the National Coalition for Cancer Survivorship. Sam graduated from Vanderbilt University and the University of Virginia Law School.

ELIZABETH GOSS, JD
Elizabeth Goss is a partner in the law and public policy firm Turner & Goss LLP. Prior to entering private practice, Elizabeth served as a Congressional aide, first to Senator Ted Kennedy (D-MA) and subsequently for ten years to Senator Dale Bumpers (D-AR). Her Senate work concentrated on public health policy and biomedical research funding and regulation. Elizabeth’s clients include a number of non-profit entities interested in access to quality health care and the development of new therapies for cancer and other life-threatening diseases. Her clients include the National Coalition for Cancer Survivorship, Lymphoma Research Foundation, and Cystic Fibrosis Foundation, as well as the Cancer Leadership Council, a coalition of cancer organizations. She graduated from Harvard College and Georgetown University Law Center.